SnapShot: Immune Checkpoint Inhibitors

Gabriel Abril-Rodriguez; Antoni Ribas

doi:10.1016/j.ccell.2017.05.010

SnapShot: Immune Checkpoint Inhibitors

Cancer Cell. 2017 Jun 12;31(6):848-848.e1. doi: 10.1016/j.ccell.2017.05.010.

Authors

Gabriel Abril-Rodriguez¹, Antoni Ribas²

Affiliations

¹ Department of Medicine, Division of Hematology-Oncology, University of California, Los Angeles, CA 90095, USA.
² Department of Medicine, Division of Hematology-Oncology, University of California, Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center, Los Angeles, CA 90095, USA.

PMID: 28609660
DOI: 10.1016/j.ccell.2017.05.010

Abstract

Immunotherapy has changed the landscape of cancer treatment. Checkpoint blockade therapies unleash breaks in the immune system and induce long-lasting responses. However, a significant number of patients do not respond (innate resistance), and a subset progress after responding (acquired resistance). A better understanding of the molecular mechanisms underlying checkpoint blockade therapies will facilitate the design of novel strategies to treat and prevent resistance. To view this SnapShot, open or download the PDF.

MeSH terms

Adaptive Immunity / drug effects
Cell Cycle Checkpoints / drug effects
Drug Resistance, Neoplasm / immunology
Humans
Immunotherapy / methods*
Interferons / drug effects
Interferons / physiology
Neoplasms / drug therapy*
Neoplasms / immunology

Substances

Interferons